載入...
Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition
The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...
Na minha lista:
| 發表在: | Brain Commun |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7425526/ https://ncbi.nlm.nih.gov/pubmed/32954282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/braincomms/fcaa021 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|